Abstract 173P
Background
This retrospective multicenter real-world study aims to compare outcomes reached by L and S second-line therapy in HCC patients treated with first-line AB.
Methods
The overall cohort included 891 HCC patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea) treated with AB in first-line setting between October 2018 and April 2022. A total of 472 (53.0%) patients had progressive disease after first-line therapy, of which 243 (51.5%) received a second-line treatment. Data from 137 patients were available for the analysis: 51 (37.2%) received S and 86 (62.8%) L.
Results
L second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; HR: 2.24) compared to S subgroup that reached a mOS of 14.3 months. After adjusting for positive clinical covariates at univariate analysis, multivariate analysis highlighted Albumin-Bilirubin (ALBI) 1 grade [p < 0.01; hazard ratio (HR): 5.23] and L second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factor for OS. Forest plot highlighted a positive trend in terms of OS in favor of patients treated with L second-line regardless of baseline characteristics before first-line therapy. In particular, L second-line subgroup had a better OS compared to S second-line subgroup in male patients, aged ≤ 70 years, with viral etiology, Barcelona Clinic Liver Cancer C stage, αfetoprotein < 400 ng/mL, Child-Pugh A, NLR < 3, ALBI 1 grade, performance status ≤ 1, presence of portal vein thrombosis. Regarding first-line treatment outcomes, L second-line subgroup achieved a median progression-free survival (mPFS) of 3.5 months, while S second-line subgroup reached a mPFS of 4.3 months without any significative difference (p 0.42; HR: 1.15). There was no difference in overall response rate (L 26.1% vs. S 19.8%; p = 0.29) and disease control rate (L 76.8% vs. S 66.4%; p = 0.71) between the two subgroups.
Conclusions
L second-line therapy is superior to S in HCC patients progressed to first-line AB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract